Cataract Procedures Articles & Analysis
30 news found
The company Swiss Advanced Vision (SAV-IOL SA) announced today the launch of LUCIDIS and EDEN, two new intraocular lenses (IOLs) for the cataract surgery, both using the Instant Focus EDOF patented technology. With a brand-new concept, LUCIDIS brings two major achievements for the monofocal market: extending the depth of focus on a monofocal lens while being the first affordable EDOF IOL. Thanks ...
The final study results demonstrated that canaloplasty and trabeculotomy performed as an implant-free minimally invasive glaucoma surgery (MIGS) using the OMNI® Surgical System in conjunction with cataract surgery significantly reduced unmedicated mean diurnal intraocular pressure (IOP), medication use and daily fluctuations in IOP in patients with open-angle glaucoma (OAG). ...
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter and year ended December 31, 2021. Recent Business Highlights Generated 2021 total revenue of $49.0 million, an increase of 77% compared to the prior year ...
Study objectives include analyzing canaloplasty and trabeculotomy outcomes combined in one procedure and canaloplasty alone. This superiority trial will enroll 459 subjects who will be randomized in an equal allocation ratio (1:1:1) to the three study arms and followed for 12 months after surgery. ...
Melbourne, Australia – March 4, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that data from the Phase IIa study of its PA5108 Ocular Implant for the treatment of Primary Open-Angle ...
” While MIGS first entered the market as an implant-based procedure performed only at the time of cataract surgery, the OMNI® Surgical System*, an implant-free MIGS, is now cleared by the FDA more broadly for use not only in combination with cataract surgery but also as a standalone procedure to lower IOP in adult ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle glaucoma, without concurrent cataract ...
TearLab Corporation, a global ophthalmic diagnostics company marketing point-of-care laboratory testing, today announced that Adam Szaronos has been appointed President and Chief Executive Officer by the company's Board of Directors, effective immediately. Mr. Szaronos has been instrumental in leading teams and bringing innovations to market to address unmet needs throughout eye care. Mr. ...
BySOFIE
Nir Dotan was previously Vice President of Human Resources at Hanita Lenses, a medical device manufacturer and provider of intraocular lens solutions for cataract surgery, and previously served in roles handling recruitment and marketing. ...
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced publication in Clinical Ophthalmology of favorable data showing that microinvasive glaucoma surgery (MIGS) using the OMNI® Surgical System suppressed daily fluctuations in intraocular pressure ...
Combining Hydrus with cataract surgery is an opportunity to treat patients early in their disease state. With a safe glaucoma surgery like Hydrus, the procedure can be performed in mild or early onset disease before significant visual loss has ...
Bio-Tissue, Inc., a TissueTech company and pioneer in the clinical application of human birth tissue allografts to promote regenerative healing for ocular surface disease and disorders, announced today that it has entered into a Vendor Agreement with EyePro Group Purchasing Organization (GPO), LLC. As such, GPO members can now take advantage of membership purchasing volume discounts to access ...
Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corporation to settle and dismiss all pending global litigation between them. Under the agreement’s terms, Ivantis has agreed to pay a total of ...
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces enlightening findings from its primary market research with optometrists and ophthalmologists related to contact lens drug delivery and its proprietary pipeline of assets. Key learnings from the market ...
Dr. Ken Mandell, Founder and CEO of LayerBio, presented an update on the development of its novel OcuRing-K ketorolac implant for treatment of postoperative pain and inflammation with cataract surgery. To see video, please click ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever release of five-year follow-up data from its HORIZON pivotal trial. This significant milestone represents the longest continuous follow-up of a MIGS device pivotal trial and comes on the ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure in patients with open-angle glaucoma, is proud to be the recipient of multiple awards and recognition this year for its innovation and excellence in helping to change the standard of care for the world’s 80 million glaucoma patients, as well as its ...
“There are only three recommended MIGS procedures, and the evidence for Hydrus was rated as the strongest. This is an important validation of the Hydrus device and its potential impact for our ...
After insertion, EndoArt® unfolds itself and is attached to the posterior corneal surface using the air bubble technique, similar to a DSAEK or DMEK procedure; at this stage, it is possible to manipulate the implant as needed, which results in an easier and safer surgical technique. Corneal surgeons who have performed endothelial keratoplasty (EK) will be able to implant ...
The company’s IOP Connect™ system is based on a long-term implantable sensor, smaller than a grain of rice, that is delivered to the eye by injection during a five-minute in-office procedure. The BDP designation is intended to help patients and physicians receive more timely access to breakthrough technologies that have the potential to provide more effective ...